Frede Donskov

Denmark

Research Interests

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (14)

Lone Sunde

Aarhus University

DENMARK

View details

Erik Morre Pedersen

Aarhus University

DENMARK

View details

Signe Beck-Nielsen

Aarhus University

DENMARK

View details

Nessn Azawi

Zealand University Hospital

DENMARK

View details

Morten Nørgaard Andersen

Aarhus University

DENMARK

View details

Jens Folke Kiilgaard

Københavns Universitet

DENMARK

View details

Ove B. Schaffalitzky de Muckadell

Odense University Hospital

DENMARK

View details

Marie Louise Mølgaard Binderup

Københavns Universitet

DENMARK

View details

Kirstine Stochholm

Aarhus University Hospital

DENMARK

View details

Lennart Friis-Hansen

Odense University Hospital

DENMARK

View details

Naomi Nadler

Zealand University Hospital

DENMARK

View details

Bernadett Szabados

Barts Cancer Institute

UNITED KINGDOM

View details

Susanne Oksbjerg Dalton

Professor, Head of COMPAS Danish Research Center for Equality in Cancer

Zealand University Hospital Køge

DENMARK

View details

Bradley McGregor

Harvard University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Frede Donskov

Research Interests

Contact this professor

Articles (10)

Late adverse events to iodinated contrast media in patients treated with IL-2

Soluble CD163

Lifestyle and Clinical Factors in a Nationwide Stage III and IV Renal Cell Carcinoma Study

Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma

Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy

von Hippel-Lindau disease

CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).

Molecular analysis and favorable clinical outcomes in real-world patients with metastatic renal cell carcinoma

Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010)

Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy

Collaborators (14)

Lone Sunde

Erik Morre Pedersen

Signe Beck-Nielsen

Nessn Azawi

Morten Nørgaard Andersen

Jens Folke Kiilgaard

Ove B. Schaffalitzky de Muckadell

Marie Louise Mølgaard Binderup

Kirstine Stochholm

Lennart Friis-Hansen

Naomi Nadler

Bernadett Szabados

Susanne Oksbjerg Dalton

Bradley McGregor

Make your next move.